23andMe Names Dr. Ashley Ledbetter Dombkowski Chief Business Officer
July 5, 2011
Dr. Dombkowski to Lead 23andMe’s Global Translational Collaborations
Mountain View, Calif. – July 5, 2011 – Today 23andMe, an industry leader in personal genetics, announced the appointment of Ashley Ledbetter Dombkowski, PhD as Chief Business Officer. Dr. Dombkowski will assume global responsibility for 23andMe’s translational collaboration initiatives and will join the company’s executive leadership team reporting directly to 23andMe CEO and Co-Founder Anne Wojcicki. Dr. Dombkowski had previously been a member of 23andMe’s Board of Directors. “Ashley’s remarkable ability to bring strategic vision to cutting edge technologies has resulted in increased levels of innovation, productivity and success for health care companies,” said Wojcicki. “We are confident her extensive experience working with physicians, academic researchers, patient-advocacy groups and entrepreneurs will complement the world-class expertise 23andMe has assembled in genetics, medicine, information technology, ancestry, privacy and consumer-focused fields. Ashley shares 23andMe’s goal of empowering individuals with their own genetic information and working to facilitate and accelerate research on their behalf. I’m delighted to welcome her to the company in this new, fully-dedicated role.” “23andMe has pioneered a compelling approach to genetics by allowing individuals to learn from and interact with their own DNA while also contributing to research that could improve their lives,” said Dombkowski. “As a result of the company’s web-based research and rapidly growing database, the platform has already demonstrated unprecedented research utility. My aim is to ensure that discoveries made by, and on behalf of, our community can be translated so that users are not only participating in research, but benefiting from it.” Dombkowski joins 23andMe after eleven years at MPM Capital where she served as Managing Director and a member of the firm’s Investment Committee. Prior to MPM she was a Health Care Analyst at Tiger Management and Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and a B.A. in Mathematics from Wellesley College.
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.